Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).

Lazaros AndronisIlias GoranitisSarah PirrieAnn PopeDarren BartonStuart CollinsAdam DauntonDuncan McLarenJoe M O'SullivanChris ParkerEmilio PorfiriJohn StaffurthAndrew StanleyJames WylieSharon BeesleyAlison BirtleJanet E BrownPrabir ChakrabortiSyed A HussainJ Martin RussellLucinda J BillinghamNicholas D James

Published in: BJU international (2016)

The addition of bone-targeting treatments to standard chemotherapy led to a small improvement in QALYs for a modest increase in cost (or cost-savings). ZA and Sr89 resulted in ICERs below conventional willingness-to-pay per QALY thresholds, suggesting that their addition to chemotherapy may represent a cost-effective use of resources.

Keyphrases

prostate cancer
locally advanced
bone mineral density
radical prostatectomy
clinical trial
soft tissue
study protocol
squamous cell carcinoma
rectal cancer
randomized controlled trial
bone regeneration
health insurance
bone loss
radiation therapy
phase iii
open label